[go: up one dir, main page]

CL2019000236A1 - Composición y uso de un péptido. - Google Patents

Composición y uso de un péptido.

Info

Publication number
CL2019000236A1
CL2019000236A1 CL2019000236A CL2019000236A CL2019000236A1 CL 2019000236 A1 CL2019000236 A1 CL 2019000236A1 CL 2019000236 A CL2019000236 A CL 2019000236A CL 2019000236 A CL2019000236 A CL 2019000236A CL 2019000236 A1 CL2019000236 A1 CL 2019000236A1
Authority
CL
Chile
Prior art keywords
peptide
composition
seq
diseases
unattended
Prior art date
Application number
CL2019000236A
Other languages
English (en)
Inventor
Maria Carolina Quartim Barbosa Elias Sabbaga
Christiane Bezerra De Araujo
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102016017666-2A external-priority patent/BR102016017666B1/pt
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CL2019000236A1 publication Critical patent/CL2019000236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSICIÓN QUE COMPRENDE UN PÉPTIDO SEGÚN SE DEFINE EN SEQ ID Nº 1, 3, 4 Ó 5 Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE. USO DE UN PÉPTIDO SEGÚN SE DEFINE EN SEQ ID Nº 1, 3, 4 Ó 5 EN LA MANUFACTURA DE UNA COMPOSICIÓN FARMACÉUTICA PARA TRATAR ENFERMEDADES DESATENDIDAS. MÉTODO PARA TRATAR ENFERMEDADES DESATENDIDAS.
CL2019000236A 2016-07-29 2019-01-29 Composición y uso de un péptido. CL2019000236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016017666-2A BR102016017666B1 (pt) 2016-07-29 Composição, e, uso de um peptídeo

Publications (1)

Publication Number Publication Date
CL2019000236A1 true CL2019000236A1 (es) 2019-06-07

Family

ID=59626401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000236A CL2019000236A1 (es) 2016-07-29 2019-01-29 Composición y uso de un péptido.

Country Status (5)

Country Link
AR (1) AR109199A1 (es)
CL (1) CL2019000236A1 (es)
CO (1) CO2019000942A2 (es)
MX (1) MX2019001320A (es)
WO (1) WO2018018121A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909254B (zh) * 2019-05-10 2024-08-20 国家纳米科学中心 抑制肿瘤活性的多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102014000521B1 (pt) 2014-01-09 2021-05-25 Proteimax Biotecnologia Ltda peptídeo, uso, composição farmacêutica, método in vitro de inibição ou de identificação de células em divisão

Also Published As

Publication number Publication date
AR109199A1 (es) 2018-11-07
WO2018018121A1 (en) 2018-02-01
MX2019001320A (es) 2019-09-19
CO2019000942A2 (es) 2019-02-08
BR102016017666A2 (pt) 2018-02-14

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
MX2021002321A (es) Nuevos metodos.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
CO2018003542A2 (es) Anticuerpo anti-garp
MX2021002322A (es) Nuevos metodos.
HK1248115A1 (zh) 一种使用免疫调节治疗癌症的新颖方法
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018013517A (es) Anticuerpos anti-il-1r3 humanizados.
SG10201902594QA (en) Peptidomimetic macrocycles and uses thereof
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
MX2019004314A (es) Composición de apósito tópico para el tratamiento de tejido cutáneo dañado.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AU2017268795A1 (en) Methods of treating behavioral syndromes using pipradrol
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
MX2019013862A (es) Terapia de combinacion.